 Eli Lilly & Co. said the U.S. Food and Drug Administration won't approve its new drug application for a type-2 diabetes treatment until issues at the product manufacturing facility are resolved.. Lilly said Wednesday that it received a complete response letter from the FDA that referenced deficiencies at the Boehringer Ingelheim Pharmaceutical Inc. facility where its diabetes treatment, empagliflozin, will be manufactured.. A...
  